Series A AI companies in London

Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide.For more information, please visit www.verdivabio.com.

• Series A
• 79 employees
• Founded 2024

Proteins are at the heart of every biological process, yet today’s tools still leave major blind spots. At Portal Biotech, we're developing the first platform capable of sequencing entire proteins at the single-molecule level, replacing fragmented views with a complete picture. We want to empower scientists to understand proteins in depth and in real time, enabling faster drug discovery, more accurate diagnostics, and stronger pandemic readiness. Portal Biotech was founded by DNA-sequencing veterans, leveraging machine-learning algorithms and building on decades of in-house expertise in nanopore technology. By analysing full-length protein molecules at the single-molecule level, our platform delivers rapid, real-time information on protein identity, abundance, and structure. Those insights open frontiers in drug discovery, diagnostics, and fundamental research, helping scientists and clinicians to better understand human health and disease.We’re looking for sharp minds to help bring this vision to life.

• Series A
• 73 employees
• Founded 2021

To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours.Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates.We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.

• Series A
• 65 employees
• Founded 2016

Shellworks is a design-led material innovation company creating uncompromising, sustainable packaging and consumer goods made from VIVOMER.VIVOMER is a plastic-free material that behaves just like plastic in use. It can be made flexible or rigid, and inherently exhibits barrier properties that make it shelf-stable for years. Unlike plastic however, VIVOMER is microplastic, BPA and PFAS free, and is fully home compostable. VIVOMER is engineered to last as long as you need it to. It just doesn't last forever.We've just launched the first product we've made for ourselves, the VIVOMER cutting board. Now available on our website!

• Series A
• 50 employees
• Founded 2019

Mytos automates production of stem cell-derived therapies - enabling them to scale to millions of patients at low cost. Our custom iDEM robotics platform powers our automated CDMO.Our announced partnerships include neurons for treating Parkinson's, bone for bone repair, corneal cells for blindness, and auditory neurons for hearing loss (and we have more to announce). Cells produced on our iDEM platform will be going into patients by 2027.Mytos has raised over $24m from leading investors, including YCombinator, Buckley Ventures and IQ Capital - as well as founders and execs from companies like Kite, Sana, Dropbox, and Revolut. Our team is made up of brilliant engineers from companies like Dyson and Autodesk - working hand-in-hand with Nature-published scientists. We're hiring now - visit our website to see open positions

• Series A
• 47 employees
• Founded 2016